GRAIL, LLC (GRAL)vsNatera Inc (NTRA)
GRAL
GRAIL, LLC
$62.10
-9.87%
HEALTHCARE · Cap: $2.57B
NTRA
Natera Inc
$228.80
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 1502% more annual revenue ($2.50B vs $156.12M). NTRA leads profitability with a -9.1% profit margin vs -253.2%. GRAL earns a higher WallStSmart Score of 35/100 (F).
GRAL
Hold35
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 28.1% year-over-year
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of -15.8% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 18.4x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 28.1% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
GRAL profiles as a growth stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GRAL scores higher overall (35/100 vs 31/100) and 28.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a pioneering biotechnology company at the forefront of cancer diagnostics, focusing on innovative blood tests for multi-cancer early detection (MCED) that utilize its proprietary genomic technologies. Committed to advancing precision medicine, GRAIL aims to transform the oncology landscape by providing individuals with essential insights for proactive health management and improving overall patient outcomes. Its groundbreaking efforts address significant unmet needs in cancer screening and diagnostics, positioning the company as a key player in the rapidly evolving field of cancer care.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?